Article Text

Download PDFPDF

P153/189  Economic impact of improved functional outcomes associated with the embotrap device vs. trevo retriever and solitaire revascularization device for treatment of acute ischemic stroke: an economic analysis of mastro i from a german hospital perspective
  1. Osama Zaidat1,
  2. Mina Kabiri2,
  3. Shanti Scheffler3,
  4. Emilie Kottenmeier4,
  5. Tommy Andersson5;6
  1. 1Mercy St Vincent Medical Center, Toledo, OH, USA
  2. 2Johnson and Johnson, Health Economics and Market Access, New Brunswick, NJ, USA
  3. 3Johnson and Johnson, Health Economics and Market Access, Zug, Switzerland
  4. 4Cardiovascular and Specialty Solutions Group, CERENOVUS, Irvine, CA, USA
  5. 5Karolinska University Hospital and Clinical Neuroscience Karolinska Institute, Stockholm, Sweden
  6. 6AZ Groeninge, Kortrijk, Belgium
  7. *Live Presentation


Introduction Stroke is a leading cause of death and disability globally, with an estimated European economic burden of €45 billion annually. The MASTRO I meta-analysis found the use of the EmboTrap Revascularization Device during mechanical thrombectomy (MT) resulted in higher rates of good functional outcomes (90-day mRS 0–2) compared to the Trevo Retriever and Solitaire Revascularization Device.

Aim of Study This analysis estimates the cost-consequence of stent retriever (SR) choice based on results reported in MASTRO I.

Methods A cost analysis with a German hospital (short-term) perspective was developed using a decision tree to simulate index hospitalization costs for a cohort of acute ischemic stroke patients achieving mRS 0–2 vs 3–5 treated with EmboTrap, Trevo or Solitaire. Short-term costs were calculated per device based on hospital length of stay by mRS level and reported inpatient cost per day. Patients who died within 90-days of treatment (mRS 6) were excluded. Hospital cost savings were reported.

Results Assuming price parity across all three SRs, total per-patient short-term index hospitalization costs for EmboTrap, Trevo and Solitaire were €12.723, €13.328, €13.482, respectively, resulting in cost savings favoring EmboTrap of €604 vs Trevo and €759 vs Solitaire. Cost savings persisted in sensitivity analysis based on varying premium pricing by 5–10% for EmboTrap.

Conclusion The use of EmboTrap in Germany may lead to reduction in short-term hospital costs, compared to Solitaire or Trevo due to improved patient functional outcomes (90-day mRS 0–2). These findings may inform evidence-based decision making when selecting a cost-efficient SR for MT.

Disclosure of Interest Osama Zaidat reports consulting fees for Stryker, Medtronic, Cerenovus, and Penumbra; research grants from Stryker, Medtronic, Cerenovus, Penumbra, and Genentech; in addition, Dr Zaidat had a patent for ischemic stroke issued.

Tommy Andersson is a consultant for Anaconda, Cerenovus, Neuravi and Rapid Medical, and holds equity in Ceroflo.

Mina Kabiri is an employee of Johnson & Johnson.

Shanti Scheffler is an employee of Johnson & Johnson.

Emilie Kottenmeier is an employee of Johnson & Johnson.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.